Mirum Pharmaceuticals, Inc

Vifor Pharma is a global leader in iron deficiency and nephrology, dedicated to improving the lives of patients with severe and chronic diseases. With a strong presence worldwide, they strive to provide innovative therapies and solutions for those suffering from chronic kidney disease. Committed to transparency and patient well-being, Vifor Pharma conducts investigator-initiated studies and offers a range of nephrology products to address the specific needs of patients. Their mission is to help individuals lead better, healthier lives by providing effective treatments and support for chronic conditions.Generated from the website

Ardelyx, based in Fremont, CA, is a pioneering biopharmaceutical company dedicated to advancing patient care through the development of targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. With a focus on translating scientific breakthroughs into promise for patients, Ardelyx utilizes a unique and innovative platform to discover new biological mechanisms and pathways for creating oral, small molecule therapies. Driven by values of passion, fearlessness, and dedication, Ardelyx is committed to making a difference for patients by bringing integrity and innovation to the forefront of their work. Through their relentless pursuit of developing medicines that matter, Ardelyx aims to improve patient outcomes and contribute to the advancement of healthcare.Generated from the website

Alexza Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The company's technology, the Staccato system, vaporizes unformulated drug compound to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. Alexza Pharmaceuticals has four product candidates in clinical development: AZ-001 (Staccato prochlorperazine) for the treatment of acute migraine headaches; AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder; AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia; and AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain. Alexza Pharmaceuticals is located in Palo Alto, Calif.